Viral Vector Gene Therapy for Diabetic Retinopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic retinopathy, particularly those involving repeated injections of VEGF inhibitors, face challenges in maintaining consistent antibody levels, leading to peak and trough effects and increased risk of complications, while directly injected antibodies may contain degradation products and have different bioactivity and immunogenicity profiles.
Innovation Solution
Gene therapy using a viral vector encoding a fully human post-translationally modified antigen-binding fragment of a monoclonal antibody against VEGF, such as a glycosylated antigen-binding fragment, is delivered to the suprachoroidal or subretinal space to create a permanent depot that continuously supplies the antibody, leveraging human retinal cells for post-translational modification and reducing immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated injections of VEGF inhibitors are administered, then therapeutic effect is maintained, but peak and trough effects occur and complication risk increases
Solution Approach 1:
The patent applies preliminary action by delivering a viral vector that encodes the antibody sequence before therapeutic need arises. The vector establishes a permanent depot in retinal cells that continuously produces the antibody, proactively eliminating the need for repeated injections and preventing peak-trough fluctuations before they can occur.
Solution Approach 2:
The patent implements self-service by enabling retinal cells to autonomously produce the therapeutic antibody through the delivered viral vector. The cells continuously synthesize and secrete the antibody themselves, eliminating dependency on external repeated administrations and maintaining consistent therapeutic levels without human intervention.
2Speed
If directly injected antibodies are used, then immediate therapeutic effect is achieved, but degradation products and immunogenicity issues arise
Solution Approach 1:
The patent implements self-service by enabling retinal cells to autonomously produce the therapeutic antibody through the delivered viral vector. The cells continuously synthesize and secrete the antibody themselves, eliminating dependency on external repeated administrations and maintaining consistent therapeutic levels without human intervention.
Solution Approach 2:
The patent applies parameter changes by modifying the antibody to be fully human post-translationally modified, specifically human-glycosylated. This structural parameter change reduces immunogenicity and improves stability, allowing the antibody to be produced locally without generating harmful degradation products or immune responses.
3Reliability
If fully human post-translationally modified antibody is produced locally, then immunogenicity is reduced and consistent levels are maintained, but complex delivery system is required
Solution Approach 1:
The patent uses a viral vector as an intermediary carrier to deliver the antibody-encoding sequence to retinal cells. This intermediary facilitates the complex process of establishing permanent, localized antibody production without requiring direct injection of complex therapeutic systems, simplifying the overall delivery approach while achieving reliable consistent levels.
Data Source
AI summary
Compositions and methods are described for the delivery of a fully human post-translaionally modified (HuPTM) monoclonal antibody (“mAh”) or the antigen-binding fragment of a mAh against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy.